Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Δευτέρα 31 Οκτωβρίου 2016

Differences in type composition of symptom clusters as predictors of quality of life between patients with meningioma and glioma.

Differences in type composition of symptom clusters as predictors of quality of life between patients with meningioma and glioma.

World Neurosurg. 2016 Oct 26;:

Authors: Kim SR, Shin YS, Kim JH, Choi M, Yoo SH

Abstract
OBJECTIVE: The purposes of this study were to identify and compare symptom clusters in patients with meningioma and glioma, and to assess and compare predictors of quality of life (QoL) in both patient groups.
METHODS: Data were collected using the MD Anderson Symptom Inventory Brain Tumour Module, the Functional Assessment of Cancer Therapy-General, and the Karnofsky Performance Scale (KPS). Of the 158 participating patients, 77 had meningioma and 81 had glioma.
RESULTS: Four symptom clusters were identified with 55.4% total variance in patients with meningioma. These clusters were 1) physical, 2) cognitive, 3) elimination-appearance, and 4) motor-sensory symptoms. In patients with glioma, four clusters with a total variance of 67.3% were identified: 1) treatment-related, 2) cognitive, 3) appearance-elimination, and 4) gastrointestinal symptoms. Predictors of QoL were KPS score (β = 0.41, p < .001), cognitive symptom cluster (β = -0.36, p < .001), and physical symptom cluster (β = -0.32, p = .001) in patients with meningioma whereas treatment-related symptom cluster (β = -0.55, p < .001) was identified as the predictor of QoL in patients with glioma.
CONCLUSIONS: This study demonstrates that the type and composition of symptom clusters differed between patients with meningioma and glioma. In addition, our data provide evidence that even when the participants reported mild symptoms, these clusters could be used to predict QoL in patients with meningioma and glioma.

PMID: 27794512 [PubMed - as supplied by publisher]



http://ift.tt/2f8I2aJ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου